Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Bristol Myers Squibb presented follow-up clinical data for Camzyos (mavacamten) showing long-term efficacy and safety trends out to five years. The update is framed as reinforcing the therapy’s durability of benefit and tolerability, which is modestly supportive for investor sentiment. Market impact is likely limited without new quantifiable endpoints in the excerpt.